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ABSTRACT
Promising targeted treatments and immunotherapy strategies in oncology and 
advancements in our understanding of molecular pathways that underpin cancer 
development have reignited interest in the tumor-associated antigen Folate Receptor 
alpha (FRα). FRα is a glycosylphosphatidylinositol (GPI)-anchored membrane protein. 
Its overexpression in tumors such as ovarian, breast and lung cancers, low and 
restricted distribution in normal tissues, alongside emerging insights into tumor-
promoting functions and association of expression with patient prognosis, together 
render FRα an attractive therapeutic target. In this review, we summarize the role of 
FRα in cancer development, we consider FRα as a potential diagnostic and prognostic 
tool, and we discuss different targeted treatment approaches with a specific focus on 
monoclonal antibodies. Renewed attention to FRα may point to novel individualized 
treatment approaches to improve the clinical management of patient groups that do 
not adequately benefit from current conventional therapies.
INTRODUCTION
Water soluble vitamin B9 can occur as ‘folate’ 
(enriched in dark leafy vegetables) and as ‘folic 
acid’ (a synthetic folate compound used as a vitamin 
supplement). A sufficient intake of folate is needed in 
rapidly proliferating cells for the one-carbon metabolic 
reaction and DNA biosynthesis, repair and methylation 
[1]. Dysregulated folate metabolism has been associated 
with embryonic developmental disorders, cardiovascular 
disease and brain defects [2-4]. Folate is transported 
across the cellular membrane in three ways. The main 
route of uptake is through the reduced folate carrier (RFC), 
which is ubiquitously distributed and aids the uptake of 
dietary folate [5]. The second route is through the proton-
coupled folate transporter (PCFT), which utilizes the 
transmembrane proton gradient to mediate folate transport 
into the cells [6]. Finally, folate can be transported by 
folate receptors, of which there are four glycopolypeptide 
members (FRα, FRβ, FRγ and FRδ), with molecular 
weights ranging from 38 to 45 kDa [7]. The alpha isoform, 
Folate Receptor α (FRα), also known as FOLR1 or folate 
binding protein (FBP), is a glycosylphosphatidylinositol 
(GPI)-anchored membrane protein with high affinity for 
binding and coordinating transport of the active form of 
folate, 5-methyltetrahydrofolate (5-MTF) [8, 9].
FRα has been reported to be overexpressed in solid 
tumors such as ovarian, lung and breast carcinomas [10-
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12]. On the other hand, the distribution of FRα in normal 
human tissues is restricted to low level expression in the 
apical surfaces of some organs such as the kidney, lung 
and choroid plexus [9]. Studies have demonstrated that 
overexpression of FRα may render a growth advantage for 
cancer cells through mechanisms both relating to, as well 
as being independent of, folate uptake [13, 14]. 
Here, we review FRα as a folate carrier and a tumor-
associated signalling molecule in relation to its potential 
as a target, and as a diagnostic and prognostic tool, in 
oncology. We describe examples of past and present 
treatment approaches and promising therapeutic avenues, 
with specific focus on monoclonal antibodies for ovarian, 
lung and breast cancer, as examples of FRα-positive 
malignancies.
FRα-MEDIATED INTERNALIZATION 
OF FOLATES AND REGULATION OF 
CANCER SIGNALING
Traditionally FRα is described as a transporter to 
internalize folate. Folate trafficking via FRα is thought to 
occur by a non-classical lipid raft-mediated endocytosis 
pathway, namely potocytosis, which does not involve 
clathrin-coated pits. This pathway is associated with 
caveolae vesicles [15]. Folate binds specifically to 
FRα creating a receptor-ligand complex; then through 
invagination and budding off, intracellular vesicles 
are formed. Once internalized, the vesicles uncoat and 
single vesicles join together forming early endosomes, 
which undergo acidification and subsequent fusion with 
lysosomes to release folates for the one-carbon metabolic 
reaction [16, 17]. 
FRα overexpression in different solid tumors can 
potentially contribute to cancer development in different 
ways. A number of studies have suggested parallel roles of 
FRα in both cell growth regulation and signaling functions. 
Boshnjaku et al. reported that following folate uptake and 
internalization, FRα can then translocate to the nucleus 
and act as a transcription factor, binding to cis-regulatory 
elements. Through this mechanism, FRα may directly 
regulate the expression of key developmental genes in 
cancer cells [18]. Ovarian cancer cells transfected with a 
single-chain intrabody targeting FRα showed reduced cell 
surface expression and subsequent impaired tumor cell 
proliferation, reduced colony formation, and dysregulated 
adhesion; together signs of reversing tumor cell 
transformed phenotype [19]. Furthermore, folate uptake 
can promote cancer cell proliferation, migration and loss of 
adhesion through downregulation of the cell-cell adhesion 
molecule, E-cadherin, promoting cellular motility and 
metastasis. In concordance, it was also reported that 
the absence of E-cadherin expression correlated with 
decreased patient survival in ovarian carcinomas [20]. 
FRα knockdown in ovarian carcinoma cell lines could 
inhibit folate-mediated cell proliferation and suppress an 
invasive phenotype [14]. FRα has also been demonstrated 
to inhibit caveolin-1, thereby supporting anchorage-
independent growth and proliferation of tumor cells and 
promoting cancer progression [21, 22]. 
More recently, FRα has been demonstrated to 
contribute to cancer malignancy by acting as a signaling 
molecule. Similarly to other GPI family proteins, FRα 
is thought to initiate intracellular regulatory signaling 
networks upon binding with folate. FRα overexpression 
has been reported to be associated with increased STAT3 
signaling [23]. Hansen et al. demonstrated that folate 
binding to FRα could induce STAT3 activation via a 
GP130 co-receptor-mediated JAK-dependent process 
[24]. Moreover, phosphorylated LYN tyrosine kinase was 
found in anti-FR mAb precipitates of FRα-expressing 
tumor cell lysates [25]. These findings suggest the receptor 
has the potential to form macromolecular complexes in 
which FRα can trigger intracellular signaling. The basal 
subtype of breast cancers have been observed to express 
high levels of LYN, which has been reported to regulate 
the phosphorylation of a non-receptor tyrosine kinase, 
PEAK1, to promote ERK and STAT3 activation, as well as 
to support cellular transition to a mesenchymal phenotype, 
increasing cell motility and invasion [26]. Furthermore, 
FRα overexpression is frequently reported to be expressed 
in metastatic foci and recurrent tumors [27], even in 
microenvironments with limited folate availability. 
Together, these studies strongly suggest that FRα 
may function not only as a folate transporter, but may also 
confer signaling and growth advantages on malignant cells 
(as depicted in Figure 1) [28].
FRα: A THERAPEUTIC TARGET, 
DIAGNOSTIC AND/OR PROGNOSTIC 
TOOL FOR THE MANAGEMENT OF 
SOLID TUMORS
FRα expression in non-malignant tissues
FRα expression has been examined by several 
methods including immunohistochemistry using 
monoclonal antibodies, folate ligand binding assays, 
measurement of mRNA levels by qPCR, and by flow 
cytometry [8, 29-31]. Expression of FRα in normal tissues 
is restricted to the luminal surface of the kidney, intestine, 
lung, retina, placenta and choroid plexus [30, 32, 33]. 
Importantly, in all normal tissues except the kidneys, the 
receptor is confined to the apical surface of the epithelium 
that is out of direct contact with folate and any folate 
receptor-targeting agents in the circulation [34, 35]. The 
FRα expressed in the kidneys functions as a salvage 
receptor to retrieve and prevent loss of folate in the urine. 
However, folate is not retained in the kidneys, and as such 
no lethal toxicities have been observed in rodent or human 
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subjects treated with FRα-targeting agents [35, 36].
FRα expression in epithelial tumors
Cancers found to overexpress FRα are often of 
epithelial origin, including cancers of the ovary, breast, 
pleura, lung, cervix, endometrium, kidney, bladder and 
brain [29, 37]. FOLR1 mRNA expression levels for 
various types of cancer have been studied (expression 
levels in cell line panels summarized in Figure 2) [38].
Ovarian cancer
In ovarian cancer, FRα is overexpressed in 80% of 
epithelial ovarian cancers (EOCs) and expression has been 
shown to significantly correlate with histological grade 
and stage [10, 14]. The expression of FRα is considered 
a marker of tumor aggressiveness, and although there is 
conflicting data when all ovarian carcinoma histotypes are 
considered, elevated FRα expression is associated with 
lower disease-free interval (DFI) and poor overall survival 
(OS) in patients with disease of serous origin [27, 39].
FRα is also thought to facilitate resistance to 
chemotherapy in ovarian carcinoma patients, with 
higher tissue FRα expression associated with lower 
response rate to chemotherapeutic agents [28, 39, 40]. 
Nevertheless, a number of studies have shown that FRα 
tumor surface expression does not differ between paired 
samples before and after chemotherapy. This suggests that 
chemotherapeutic agents do not affect antigen expression 
and FRα-positivity can be used to detect recurrent disease 
[41, 42] and strengthen the rationale for the potential 
utility of FRα-targeting therapeutics for both newly 
diagnosed and recurrent disease.
Lung cancer
Non-small cell lung cancer (NSCLC) accounts 
for 80% of lung cancers. Despite advances in 
surgical techniques, radiotherapeutic approaches and 
chemotherapy regimens, and the development of novel 
molecular targeted agents, the prognosis is poor with a 
5-year all-stage survival rate of 21% [11]. Both common 
subtypes of NSCLC, adenocarcinoma and squamous cell 
Figure 1: A model depicting FRα-mediated internalization of folates and regulation of cancer signaling. 1) Folate binding 
to FRα could induce STAT3 activation via a GP130 co-receptor mediated JAK-dependent process. 2) FRα may form macromolecular 
complexes with LYN tyrosine kinase, which has been reported to regulate the phosphorylation of PEAK1 to promote ERK and STAT3 
activation. 3) GPI-anchored FRα is internalized in caveolae vesicles and forms early endosomes, which undergo acidification and subsequent 
fusion with lysosomes to release FRα and folate. FRα is then translocated to the nucleus and acts directly as a transcription factor. 4) FRα 
acts as a folate transporter; a sufficient intake of folate is needed in rapidly proliferating cells for the one-carbon metabolic reaction and 
DNA biosynthesis, repair and methylation.
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carcinomas (SCCs), to a lesser degree, have been reported 
to express high levels of FRα [43-46]. The level of FRα 
expression by tumor cells was shown to be associated with 
improved OS in patients with resected adenocarcinomas 
[46]. Similarly, in another study, higher FRα expression 
levels were observed in well-differentiated, earlier stage 
lung tumors compared to more poorly-differentiated 
tumors from advanced stage adenocarcinoma patients, 
and higher FOLR1 gene expression levels correlated with 
significantly higher 3-year disease free survival (DFS) and 
OS rates in this cohort as well [44]. Most recently, the 
validity of FRα-targeting therapies, has been strengthened 
by observed concordance of high FRα levels between 
biopsies, primary tumors and metastases in these patients 
[11].
Overexpression of FRα has also been detected 
in up to 72% of patients with another uncommon and 
aggressive form of thoracic cancer, pleural mesothelioma 
[47, 48]. However, more studies are required to evaluate 
the diagnostic and prognostic significance of tumor FRα 
expression in mesothelioma.
Breast cancer 
A number of studies have reported overexpression 
of FRα in breast cancers [12, 49]. Most recently, high 
FRα tissue expression was observed in 74% of estrogen 
receptor (ER)/progesterone receptor (PR)-negative 
breast cancers [13, 50-52]. Steroid hormones mediate 
physiologically normal FRα regulation; in particular, 
oestrogen has been found to downregulate the expression 
of FRα. This has been demonstrated in studies that report 
a negative correlation between tumors that express ER 
and those which express FRα [13, 52]. Supporting this 
notion, drugs such as tamoxifen, which bind and inhibit 
ER function, can also cause a rise in FRα expression 
[53]. Triple negative breast cancer (TNBC), which is 
characterized by the lack of ER, PR and human epidermal 
growth factor receptor 2 (HER2), represent 10-15% of 
all breast carcinomas. Despite representing a minority of 
breast cancer cases, this particular subtype accounts for a 
disproportionate number of cases of metastatic disease and 
deaths, due to its more aggressive natural history and lack 
of available targeted therapies [54, 55]. High FRα tissue 
expression was observed in 80% of TNBCs, making it an 
attractive therapeutic target in this breast cancer type [51].
FRα expression by breast carcinomas, including 
TNBCs, is significantly associated with high histologic 
grade and advanced stage, and high proliferative activity 
as determined by expression of Ki-67. Overexpression 
of FRα was also significantly associated with poorer 
disease-free survival [49, 52]. In addition, correlation of 
high FRα expression between primary tumors and local 
and distant metastases has been observed, suggesting 
that most metastatic disease could potentially be treated 
with anti-FRα therapies when the primary tumor shows 
overexpression.
Overall, these studies, across a number of cancer 
cell types, suggest that targeting this tumor-associated 
Figure 2: FOLR1 gene expression levels in cancer models. A summary of gene expression data (generated from the Cancer Cell 
Line Encyclopaedia) showing the levels of mRNA expression for the FOLR1 gene on a logarithmic scale in various cancer cell types. 
(parentheses show number of cell lines per tumor type)
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Table 1: Key clinical trials of FRα-drug conjugate therapeutics.
Drug 
Name Alternative Name(s)
Tumor 
Type Trial Design Efficacy Outcome Safety Outcome
Imaging 
Outcome
Reference/
Trial Number
Vintafolide
(i) EC145
(ii) Folate-conjugated 
DAVLBH
Platinum-
resistant 
ovarian 
cancer
Randomized 
phase II trial 
of Vintafolide 
+ PLD vs. 
PLD alone 
in platinum-
resistant 
ovarian cancer 
(PRECEDENT)
Vintafolide 
demonstrated 
significantly 
improved clinical 
activity compared 
with PLD alone. 
Median PFS was 
5.0 and 2.7 months 
for vintafolide + 
PLD and PLD-alone 
arms, respectively (P 
= 0 .031). Greatest 
benefit observed in 
patients with 100% 
FR+ lesions, with 
median PFS 5.5 vs. 
1.5 months for PLD 
alone (P = 0.013)
Vintafolide 
+ PLD was 
well tolerated. 
Frequency of 
leukopenia, 
neutropenia, 
abdominal pain, 
and peripheral 
sensory 
neuropathy 
was higher in 
vintafolide + 
PLD vs. PLD 
arm
N/A [77]NCT00722592
FR+ 
platinum-
resistant 
ovarian 
cancer
Phase III study 
of vintafolide 
+ PLD vs. 
PLD alone in 
patients with 
FR+ platinum-
resistant 
ovarian cancer 
(PROCEED).
At a prespecified 
interim data analysis, 
cessation of the study 
was recommended 
because vintafolide 
+ PLD vs. PLD alone 
did not meet the 
prespecified criteria 
for PFS
No safety 
concerns were 
detailed
N/A [28]NCT01170650
FR+ 
NSCLC
Randomized, 
open-label, 
phase II trial 
of vintafolide 
as second-line 
treatment vs. 
vintafolide + 
docetaxel vs. 
docetaxel alone 
in patients with 
FR+ NSCLC 
(TARGET)
Preliminary data 
for vintafolide + 
docetaxel showed 
improvement 
across all efficacy 
endpoints vs. 
docetaxel alone. The 
best improvement 
was observed in 
the predefined 
adenocarcinoma 
patient subgroup
The safety profile 
was manageable 
and consistent 
with the AEs 
observed with 
both therapies
N/A
[75,  76]
NCT01577654
EC0225
(i) Folate–
desacetylvinblastine-
hydrazide 
(ii) folate–mitomycin 
C
Solid 
tumors
Phase I study 
of EC0225 in 
patients with 
solid tumors 
(refractory or 
metastatic)
Disease stabilization 
(≥ 4 months) was 
observed in 26/63 
patients
EC0225 was 
well -tolerated 
at doses ≤2.3 
mg/m2. Most 
frequent AEs 
included anemia, 
constipation, 
leukopenia, 
fatigue. G3 
hypotension and 
G4 neutropenia 
occurred in 1 
patient each at 
the highest dose 
tested (2.88mg/
m2) defining the 
MTD
N/A
[79]
NCT00441870
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antigen may offer clinical benefit to patients with unmet 
need for novel therapeutic options. The low and restricted 
distribution of FRα in normal tissues, alongside the 
presence of other folate transporters, which can process 
folates, may suggest that targeting FRα would not restrict 
all folate uptake, and may not affect normal cell survival 
or proliferation nor impair normal tissue homeostasis. 
Overexpression of FRα in the blood-accessible basal and 
lateral membranes of epithelial carcinomas, and suggested 
contributions to tumor cell growth and proliferation, 
together point to targeting FRα as an attractive and 
potentially non-toxic treatment approach. 
Soluble FRα
Membrane-associated FRα can also be released by 
proteolytic cleavage with membrane-associated protease 
and GPI-specific phospholipases [9, 56]. FRα is detected 
as a soluble form in the sera of some cancer patients 
by a number of techniques, including microfiltration, 
immunoblotting, electrochemiluminescence, and ELISA 
[23, 57-59]. Soluble FRα (sFRα) is reported to be low 
or undetected in normal human sera [23, 58]. A number 
of studies of the serum from patients with both serous 
and non-serous ovarian carcinomas have demonstrated 
elevated levels of sFRα, compared to healthy individuals. 
Importantly for the potential use of sFRα as a diagnostic 
biomarker, elevated levels of sFRα were observed even 
in early stage I/II disease [23, 59]. Furthermore, levels of 
sFRα have been reported to correlate with FIGO stage, 
histological types and tumor grade [57, 59]. Most recently, 
in a cohort of 221 patients, the prognostic significance of 
sFRα was supported by findings that patients with lower 
sFRα levels had significantly longer progression-free 
survival (PFS) than those with high serum levels. A trend 
in increasing sFRα and tumor expression levels measured 
by immunohistochemistry was also reported, suggesting 
that sFRα may offer a minimally-invasive alternative 
to predict local tumor FRα positivity and may present a 
Epofolate
(i) BMS-753493
(ii) Folate-conjugated 
epothilone A
Solid 
tumors
Phase I study of 
epothilone folate 
(BMS-753493) 
in patients with 
advanced solid 
tumors
Best overall response 
was SD in 19% 
patients. Median 
duration of response 
was 85 days. No 
correlation between 
FR status and 
response. Interim 
analysis indicated 
that the benefit risk 
profile of BMS-
753493 was not 
favorable and did 
not support further 
investigation of this 
agent
The MTD 
was reached. 
DLTs included 
ALT and AST 
elevations, 
diarrhoea, 
nausea, fatigue, 
oesophagitis 
and mucosal 
inflammation
N/A [80, 81]NCT00546247
EC0489
Folate–
desacetylvinblastine 
hydrazide with 
modified linker
Solid 
tumors
Phase I study 
of EC0489 in 
patients with 
refractory or 
metastatic 
tumors 
Not reported
Patients treated 
at 2.5mg/m2 
experienced 
toxicities 
characteristic of 
vinca alkaloids 
(e.g., mild 
neuropathy), but 
not significant 
constipation nor 
gastrointestinal-
related toxicity
N/A
[82]
NCT00852189
EC1456 Folate–tubulysin
TNBC, 
advanced 
NSCLC 
and 
ovarian 
cancer
Phase I dose-
escalation study 
of EC1456 (Part 
A) including a 
study of efficacy 
in patients with 
TNBC, advanced 
NSCLC and 
ovarian cancer 
treated at the 
MTD (Part B)
Data awaited Data awaited N/A NCT01999738
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity; G, CTCAE 
grade; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PLD, pegylated 
liposomal doxorubicin; SD, stable disease; TNBC, triple negative breast cancer. Clinical trial number (NCT) available from: 
http://clinicaltrials.gov.
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surrogate marker for FRα tumor expression [57].
Studies are still needed to examine sFRα levels in 
the serum of patients with breast and lung cancers in order 
to evaluate its potential as a diagnostic and prognostic 
biomarker across cancer types and in those individuals 
where other clinically-used serum biomarkers are 
absent or unhelpful in monitoring or predicting disease 
progression. In addition, studies are required to evaluate 
the potential inhibitory impact of high sFRα levels on the 
efficacy of FRα-targeting therapies. 
CLINICAL  APPLICATION OF FRα-
BASED AGENTS
A range of FRα-targeting approaches, including 
folic acid derivatives, folate drug-conjugates and small 
molecules, vaccines, T-cell therapies and monoclonal 
antibodies, have been developed for clinical application 
for both imaging and therapeutic purposes (summarized 
in Figure 3).
FRα-targeted imaging
Although there is evidence to suggest that FRα-
positive tumors can be detected by radiolabelled antibodies 
[60, 61], the use of antibodies as diagnostic or prognostic 
tools may be limited. Poor contrasts between tumor and 
non-target tissue are often achieved following prolonged 
circulation times and slow uptake by tumors [62].
Imaging of radiolabelled derivatives of folic acid 
may offer greater tissue selectivity. Folic acid derivatives 
conjugated to a variety of metal chelates have allowed 
non-invasive detection of FRα-positive tumors in both 
animal models and patients [62]. Of these probes, the 
most extensively studied is 111In-DPTA-folate, which 
demonstrated good on-target to off-tumor contrast in 
mouse models, leading to a phase I/II trial. Patients 
with newly diagnosed or suspected recurrent ovarian 
cancer were imaged by single-proton emission computed 
tomography (SPECT) using this agent. Newly diagnosed 
malignancies were detected at a sensitivity of 100% (n 
= 7), although detection of recurrent disease was more 
problematic. Overall, this agent appeared to be safe, 
Figure 3: Potential treatment approaches targeting FRα. 1) Folate drug-conjugates: chemotherapeutic agents, such as vintafolide, 
have been conjugated to folate for FRα targeting. 2) Vaccines targeting FRα: autologous dendritic cells engineered with FRα mRNA 
commence an anti-FRα immune response, mediated by T-cells. 3) Chimeric antigen receptor (CAR) T cells: CAR T cells recognizing FRα 
trigger tumor cell killing. 4) Monoclonal antibodies (direct effects): Specific recognition of FRα lead to inhibition of downstream signaling 
events that cause tumor cell death. 5) Monoclonal antibodies (immune effector cell engagement): antibodies link FRα-expressing tumor 
cells with immune effector cells that bear Fc receptors, potentiate effector cell activation and target-neutralizing functions by engendering 
antibody-dependent effector cell-mediated cytotoxicity (ADCC), phagocytosis (ADCP) or 6) complement-dependent cytotoxicity (CDC) 
activation.
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Table 2: Clinical trials of FRα-targeting vaccines and CAR T cells.
Drug Name Alternative Name(s)
Tumor 
Type Trial Design
Efficacy 
Outcome Safety Outcome
Imaging 
Outcome
Reference/Trial 
Number
Vaccines
Folate 
Immune 
EC90/GPI-
0100/EC17
Renal cell 
carcinoma
Phase I study of 
Folate Immune 
(EC90 vaccine 
administered with 
GPI-0100 adjuvant 
followed by EC17) 
in patients with 
renal cell carcinoma
1/28 (4%) 
patients had a 
PR, 15/28 (54%) 
had SD
Two DLTs seen 
(G4 anaphylaxis 
and G3 
pancreatitis). Mild 
- mod injection 
site reactions were 
most common AE 
during vaccination 
phase. Transient 
hypersensitivity 
reactions were 
most common 
during treatment 
phase
N/A [97]NCT00329368
Folate 
Immune 
EC90/GPI-
0100/EC17
Renal cell 
carcinoma
Phase I study of 
Folate Immune 
(EC90 vaccine 
administered with 
GPI-0100 adjuvant 
followed by 
EC17) in patients 
with progressive 
metastatic renal cell 
carcinoma
Trial terminated due to poor patient 
accrual N/A NCT00485563
Autologous 
dendritic 
cells 
engineered 
with FRα 
mRNA
/
FRα+ 
serous 
papillary 
ovarian 
carcinoma
Single patient report 
of a patient with 
serous papillary 
ovarian carcinoma 
at second relapse 
(platinum-resistant) 
who received a 
vaccination regimen 
with autologous 
dendritic cells 
engineered with 
mRNA encoded 
FRα
CT before 
treatment 
and 3 months 
after the last 
vaccination (13 
months total) 
demonstrated 
a PR. CA-125 
greatly reduced 
4 weeks after the 
first vaccination 
and were still 
at baseline at 
11 months after 
completion of 
vaccination
Not reported N/A [96]
CAR T Cells
CAR-T cells 
specific to 
FRα
/ Ovarian cancer
Phase I study of 
adoptive transfer 
of FRα redirected 
autologous T cells, 
either with high-
dose IL-2 (cohort 
1), or followed 
by immunization 
with allogeneic 
peripheral blood 
mononuclear cells 
(cohort 2), for 
recurrent ovarian 
cancer
No reduction in 
tumor burden 
was seen in any 
patient
5/8 (63%) patients 
in cohort 1 
experienced a G3 
– 4 AE
Lack of 
specific 
localization 
of T cells to 
tumor was 
observed 
by tracking 
111In-
labeled 
adoptively 
transferred 
T cells
[133]
AE, adverse event; DLT, dose-limiting toxicity; G, CTCAE grade; PR, partial response; SD, stable disease. Clinical trial 
number (NCT) available from: http://clinicaltrials.gov.
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and possibly an effective diagnostic tool, although this 
evaluation was limited by the small sample size of 33 
patients [63]. Another folic acid peptide derivative (EC20) 
conjugated with 99mTechnetium (99mTc-EC20), which is less 
costly and has a shorter half-life than 111In-DPTA-folate, 
has also demonstrated promising qualities in preclinical 
models of ovarian cancer [64]. Furthermore, this agent 
has demonstrated superior FRα affinity and clearance 
from the blood and kidneys, and has been used to image > 
200 patients to date, without any imaging-related adverse 
events reported [36].
By contrast, using macromolecular dendrimer 
polychelates conjugated to folic acid in magnetic 
resonance imaging (MRI) showed improved tumor to 
non-target contrast in mouse models of ovarian cancer, 
with specific accumulation in the tumor. This is thought 
to be due to a reduction in microcapillary permeation 
by the large probe molecule, and thus a greater relative 
accumulation in FRα-positive tumors [65]. A more recent 
study demonstrated the clinical promise of FRα-specific 
ultrasmall superparamagnetic iron oxides in MRI of a 
rat model of breast cancer. This agent was specifically 
retained in FRα-positive breast tumors and may also be 
useful as a non-invasive tool to diagnose and discriminate 
FRα-positivity [66].
Agents comprising folic acid conjugated to 
fluorescent dyes have been evaluated. These agents 
provide good contrast between malignant and healthy 
tissues in animal models. However, due to the optical 
qualities of the dyes, surgical opening of the cancer site 
was required to obtain images. In future it may be possible 
to use such agents in cutaneous or subcutaneous cancers, 
or to guide endoscopic or open surgery for cancer [36].
Overall, these imaging agents may allow clinical 
detection of FRα-positive tumors, which may aid diagnosis 
and disease surveillance. However, improvements in 
sensitivity and future studies to evaluate prognostic utility 
are needed to validate this approach as a clinical tool. 
Etarfolatide
Etarfolatide is a 99mTc-based imaging agent, also 
known as FolateScan, which has been the subject of 
many studies in patients with ovarian, kidney, lung 
cancer and other refractory solid tumors (NCT01686256, 
NCT01684098) [67]. The purpose of etarfolatide is use 
as a companion agent with vintafolide, to enable pre-
selection of patients with tumors expressing FRα. The 
administration of folic acid prior to etarfolatide infusion 
was shown to improve SPECT images, and a phase I 
clinical study was performed to investigate the safety and 
pharmacokinetics of etarfolatide up to 7 days following 
folic acid injection [68]. Etarfolatide has since been used 
to evaluate the tumor FRα expression of individuals in 
a number of trials (NCT00511485, NCT01577654 and 
NCT01999738).
Folate drug-conjugates
The first folate-conjugated cytotoxic agent to be 
evaluated in tumor therapy was a maytansinoid conjugate 
[69]. Since then, a series of chemotherapy agents has 
been conjugated to folate for FRα targeting, with varying 
degrees of success. Key clinical trials are summarized in 
Table 1 [70].
Vintafolide and other folate conjugates
Vintafolide, or EC145, is a folate conjugate of 
desacetylvin-blastinemonohydrazide (DAVLBH), 
a derivative of the microtubule destabilizing agent 
vinblastine [71]. Following receptor-mediated endocytosis, 
the self-immolative disulphide-linker system enables 
the release of DAVLBH into the tumor cell endosome, 
leading to inhibition of cell division and induction of cell 
death [72, 73]. The safety of vintafolide was first assessed 
in a phase I clinical study in various solid tumors [74], 
while multiple phase II and III clinical trials have been 
conducted in lung and ovarian cancer (NCT00507741, 
NCT01577654, NCT00722592, NCT00511485 and 
NCT01170650) [69].
One clinical study, EC-FV-03 (NCT00511485), 
consisted of a single-arm phase II trial that assessed 
vintafolide as a single agent in patients with lung 
adenocarcinoma, who had previously been treated 
with at least two chemotherapy regimens. Analysis of 
survival outcomes demonstrated superior median PFS 
in patients with high FRα tumor expression compared 
with those with low expression. The median OS also 
showed a trend towards improvement [75], although 
the non-randomized study design precluded drawing 
any firm efficacy conclusion given the likely prognostic 
value of FR-alpha expression. The randomized, open-
label, phase II TARGET, study (NCT01577654), has 
also recruited patients with FRα-positive non-small cell 
lung cancer. Preliminary results for vintafolide combined 
with docetaxel suggest improvement across all efficacy 
endpoints over docetaxel as single agent in the control 
arm [76].
Among the multiple clinical studies of vintafolide 
conducted on ovarian cancer patients, of particular 
interest is the open-label phase II PRECEDENT study 
(NCT00722592) [77]. In this trial, patients who had 
received more than two previous chemotherapeutics 
were randomized to receive vintafolide and PEGylated 
liposomal doxorubicin (PLD) or PLD alone until 
progression or death. Median PFS, compared to PLD 
treatment alone, was most superior in individuals with 
higher FRα expression. This was the first combination 
therapy to suggest a significant prolongation of PFS over 
standard therapy in platinum-resistant ovarian cancer 
patients [28]. The fact that FRα-negative patients (based 
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Table 3: Clinical trials of FRα-targeting monoclonal antibodies.
Drug Name Alternative Name(s) Tumor Type Trial Design Efficacy Outcome Safety Outcome
Imaging 
Outcome
Reference/Trial 
Number
Farletuzumab MORab003
Platinum-
resistant 
EOC
Phase I dose 
escalation study of 
weekly farletuzumab
Following 1 
treatment cycle 
(4 weeks): No 
objective responses. 
SD in 36% patients 
and CA-125 
reduction in 16%
No DLTs. MTD 
not reached
Radiolabeled 
tracer studies 
conducted in 3 
patients showed 
significant tumor 
uptake
[105]
NCT00428766
Platinum-
sensitive 
EOC
Phase II study of 
farletuzumab as 
single agent or in 
combination with 
a platinum and 
taxane in platinum-
sensitive, recurrent 
epithelial ovarian, 
fallopian tube or 
primary peritoneal 
cancer
Farletuzumab alone: 
0% normalised 
CA125, 30% SD as 
best response, 70% 
PD. Farletuzumab 
+ chemotherapy: 
80.9% normalised 
CA125. ORR 75%. 
In 21%, the second 
progression-free 
interval was longer 
than the first
Farletuzumab 
well-tolerated 
as single agent, 
without additive 
toxicity when 
administered with 
chemotherapy. 
SAEs in 37% 
patients – 9% 
considered 
related to 
farletuzumab
N/A [107]NCT00318370
Platinum-
sensitive 
EOC
Phase Ib safety study 
of farletuzumab, 
carboplatin and 
PLD in patients with 
platinum-sensitive 
EOC at first or 
second relapse
CR in one patient 
(7%), PRs in 10 
patients (67%), SD 
in 4 patients (27%). 
Combination 
well-tolerated - 
no farletuzumab-
related G3-4 
adverse events.
N/A [106]NCT01004380
Platinum-
sensitive 
EOC
Phase III double-
blind placebo-
controlled study of 
weekly farletuzumab 
+ carboplatin/taxane 
in platinum-sensitive 
ovarian cancer at 
first relapse. 
Median PFS 9.0 
(placebo), 9.5 
(farletuzumab 1.25 
mg/kg), and 9.7 
(farletuzumab 2.5 
mg/kg) months 
with no statistically 
significant 
difference between 
arms
Most common 
AEs across 
arms were those 
known to be 
associated with 
chemotherapy.
N/A [28]NCT00849667
Platinum-
sensitive 
recurrent 
EOC with a 
low CA125
Phase III global 
multicenter double-
blind randomized 
placebo-controlled 
trial of farletuzumab 
+ platinum and a 
taxane or PLD in 
patients with first 
relapse of platinum-
sensitive ovarian 
cancer and a low 
CA125
Data awaited Data awaited N/A NCT02289950
Platinum-
resistant 
EOC
Phase III double-
blind placebo-
controlled study of 
weekly farletuzumab 
+ paclitaxel in 
platinum-resistant 
ovarian cancer at 
relapse
Predefined criteria 
for trial continuation 
were not met.
Trial terminated N/A NCT00738699
FRα+ TNBC 
with low 
levels of 
CA125
Phase II trial of 
farletuzumab in 
FRα+ TNBC with 
low levels of CA125
Data awaited Data awaited N/A [78]
NSCLC 
(adenoCa)
Phase II randomized, 
placebo-controlled, 
multicenter study 
of a platinum 
containing doublet 
+/- farletuzumab 
in stage IV 
adenocarcinoma of 
the lung
Data awaited Data awaited N/A NCT01218516
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on etarfolatide imaging) did not benefit from vintafolide 
and PLD combination therapy, whereas patients with 
highly FRα-positive tumors did, supported the strategy 
of using an imaging agent to identify the FRα-positive 
patient population for FRα-targeted therapy. However, the 
subsequent phase III PROCEED trial, designed to further 
evaluate the clinical efficacy of vintafolide combined with 
PLD (NCT01170650) was discontinued at an interim 
analysis because the experimental arm did not meet the 
pre-specified primary outcome for PFS improvement 
required [78].
Following vintafolide, several additional folate-
conjugated agents have been studied. EC0225, a folate 
conjugated to both a vinca alkaloid and mitomycin, 
was evaluated in a phase I trial which determined the 
maximum tolerated dose (MTD) (NCT00441870) [79]. 
Results are awaited from a phase I/II trial (NCT00546247) 
of BMS-753493 (Epofolate), a folate conjugate of 
epothilone A, which is a microtubule stabilizing agent 
[80, 81]. EC0489, an analogue of vintafolide, has been 
shown to have reduced hepatic clearance [82] and its 
MTD was evaluated in a phase I trial of metastatic tumors 
(NCT00852189). EC1456, a folic acid-tubulysin small-
molecule drug conjugate, is currently undergoing phase 
I trial in patients with advanced NSCLC, ovarian cancer 
and TNBC (NCT01999738). IMGN853, an anti-FRα mAb 
conjugated with the maytansinoid, DM4 , is now being 
evaluated in a number of phase I clinical trials to evaluate 
its safety and pharmacokinetics/pharmacodynamics alone 
(NCT01609556), and in combination with chemotherapy 
and bevacizumab (NCT02606305), in patients with 
EOC and other FRα-positive tumors. Furthermore, a 
MOv18 IgG / Ovarian carcinoma
Phase I single 
infusion dose-
escalating study 
of cMOv18 IgG 
in patients with 
primary, residual or 
recurrent ovarian 
cancer
Efficacy outcomes 
not reported
No DLT 
observed. At 
doses of ³50mg 
all patients 
experienced 
G2 side effects, 
including fever, 
headache, and 
nausea/vomiting
N/A [112]
131I-cMOv18 IgG1 /
Ovarian 
carcinoma
Kinetics and tissue 
distribution of 
131I-cMOv18 IgG1 in 
patients with ovarian 
carcinoma
Not reported Not reported
Good localisation 
in ovarian 
carcinoma tissue
[33]
Ovarian 
carcinoma
Phase I study of i.p. 
radioimmunotherapy 
with 131I-mMOv18 
IgG1 in patients with 
ovarian cancer with 
minimal residual 
disease
5/16 patients had a 
CR, 6/16 patients 
had SD and 5/16 
patients had PD
Minimal 
toxicities 
observed. One 
patient mild 
and transient 
bone marrow 
suppression
N/A [111]
Ovarian 
carcinoma
Phase I study 
of i.p. and i.v. 
radioimmunotherapy 
with 131I-cMOv18 
IgG1 in patients with 
suspected ovarian 
cancer scheduled to 
undergo exploratory 
laparotomy
Efficacy outcomes 
not reported
No normal organ 
toxicity
Tumor uptake in 
ovarian cancer 
tissue 3.4% - 
12.3% ID/kg for 
i.p. and 3.6% - 
5.4% ID/kg for i.v. 
administration
[113]
125I-, 123I-, 131I-, 
cMOv18 IgG1 /
Ovarian 
carcinoma
Study of 
simultaneous i.v. 
and i.p injection 
of radiolabeled 
c-MOv18 
(using different 
radionuclides) in 
patients with ovarian 
cancer to determine 
the optimum way to 
deliver radiolabeled 
cMOv18
Not reported No AEs reported
No significant 
differences found 
in tumor:normal 
tissue and 
tumor:blood ratios 
for both i.v. and 
i.p routes. Tumor 
uptake varied 
between patients 
and within same 
patient
[61]
MOv18 IgE /
FRα+ 
advanced 
tumors
Phase I: First in 
human study of 
MOv18 IgE in 
patients with FRα+ 
advanced cancer 
Data awaited Data awaited N/A NCT02546921
AE, adverse event; cMOv18, chimeric MOv18; CR, complete response; DLT, dose-limiting toxicity; EOC, epithelial 
ovarian cancer; G, CTCAE grade; i.p., intraperitoneal; i.v., intravenous; MTD, maximum tolerated dose; NSCLC, non-
small cell lung cancer; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PLD, pegylated 
liposomal doxorubicin; PR, partial response; SAE, serious adverse event; SD, stable disease; TNBC, triple negative breast 
cancer. Clinical trial numbers (NCT) available from: http://clinicaltrials.gov.
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phase II trial, to compare the efficacy of IMGN853 to 
standard chemotherapies, is recruiting patients with FRα-
positive tumors (NCT02631876). Folate-conjugated 
carboplatin was not considered a promising therapy due 
to neutralization by folate receptor-mediated endocytosis 
[83], but several other microtubule poisons have shown 
moderate promise in in vitro and in vivo models [84, 85].
Unlike anti-FRα antibodies, folate conjugates target 
both FRα and the functional form of FRβ. This could 
potentially enable the targeting of tumors that are low in 
FRα but high in FRβ, including tumors that are infiltrated 
by large numbers of tumor-associated macrophages 
(TAMs), known to express FRβ. Targeting pro-tumoral 
TAMs with FRβ-specific agents is a widening avenue of 
research discussed in detail in other publications [86-89].
The bi-specificity of folate drug-conjugates might 
reduce the selectivity of these drugs for tumor cells, but 
may potentially expand the range of targets to include 
elements of the tumor microenvironment. A potential 
disadvantage of folate-conjugated drug delivery is that 
binding is competitively-inhibited by excess serum 
free folate. A further potential issue is the exposure of 
FRα expressed in the apical membrane of the proximal 
renal tubules following filtration of low molecular 
weight (LMW) folate conjugates [90]. While this has 
not adversely affected clinical translation of folate 
conjugates, it may affect the clinical application of LMW 
folate conjugate-based radiopharmaceuticals for targeted 
radiotherapy.
Anti-FRα small molecule drugs
Conventional anti-folate drugs, such as pemetrexed 
and methotrexate, are often carried by the high capacity 
RFC, which is ubiquitously expressed on normal and 
tumor cells, leading to non-specific activity and associated 
reductions in patient tolerability. Therefore, anti-folate 
thymidylate synthase (TS) and glycinamide ribonucleotide 
formyl transferase (GARFTase) inhibitors, with negligible 
affinity for RFC and high-affinity for FRα, have been 
developed. These anti-FRα small molecules are thought 
to be more tumor-targeted, due to the restricted expression 
of FRα on normal tissue on apical membranes away 
from the bloodstream [91, 92]. Examples of anti-FRα 
TS inhibitors include CB300638 and ONX-0801. Pre-
clinical studies of these agents have demonstrated anti-
tumor efficacy in FRα-expressing tumors, and reduced 
transportation through RFC, which is expected to confer 
reduced patient toxicity [91, 93, 94]. A limitation for anti-
FRα small molecules may be the level of FRα expression 
by target tumor cells, which needs to be sufficient to 
transport adequate amounts of the drug into the cell in 
order to inhibit TS and cause cell death. Much of the pre-
clinical studies have used cell lines and therefore future 
work will be required to determine whether the expression 
levels of FRα are sufficient for functional effects against 
patient tumors [95]. A phase I trial of ONX-0801 is now 
recruiting patients with solid tumors, expected to have 
high FRα expression, such as EOC patients, in order to 
evaluate the safety and efficacy of two dosing schedules 
(NCT02360345). 
Vaccines targeting FRα
Increased immunity to FRα has been reported 
in patients with FRα-expressing ovarian cancer in 
comparison to healthy controls, suggesting that this may 
be a target for cell-based and peptide immunotherapies 
[23]. Key clinical trials are summarized in Table 2 [70].
A case report of a single patient with ovarian 
carcinoma, vaccinated with autologous dendritic cells that 
were engineered with mRNA-encoded FRα, demonstrated 
a vaccine-induced T cell reactivity, resulting in more 
than 50% of tumor regression, as well as a reduction of 
tumor markers levels, suggesting this strategy may hold 
promise as a cancer treatment [96]. A FRα-targeted hapten 
immunotherapeutic regimen known as ‘Folate Immune’, 
which combines folate-targeted vaccine EC90, together 
with an adjuvant, GPI-0100, and a folate-hapten conjugate 
EC17, was designed to convert poorly immunogenic 
tumors to highly immunogenic tumors. Patients first 
underwent vaccination with EC90 and GPI-0100 
adjuvant to stimulate production of specific antibodies, 
and were then treated with EC17, which is thought to 
bridge antibodies with FRα-expressing tumor cells and 
trigger antibody-dependent cellular cytotoxicity and/or 
phagocytosis (ADCC/ADCP). A phase I study confirmed 
that this regimen was well tolerated in 33 patients, with 
mild to moderate injection site reactions being the most 
common adverse effects reported [97]. A phase II trial 
was then initiated in 2012to evaluate this therapeutic 
strategy in patients with metastatic renal cell carcinoma, 
but has since been terminated due to low patient accrual 
(NCT00485563).
Oncolytic virus therapy
Virotherapy is a treatment approach using wild 
type or genetically engineered viruses [98]. An attenuated 
measles virus has been evaluated pre-clinically as FRα 
targeting treatment for ovarian cancer. The anti-tumor 
activity of oncolytic measles virus highly specific for FRα 
(MV-αFR) was tested in a xenograft model of ovarian 
cancer. Treatment of human ovarian cancer-bearing mice 
with MV-αFR resulted in significant inhibition of tumor 
growth compared to controls and 50% of mice showed 
complete regression of tumors. These findings suggested 
the merit of clinically testing the oncolytic virotherapy 
approach in FRα-expressing tumors [99].
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Monoclonal antibodies
Monoclonal antibodies (mAbs) can target tumor-
associated antigens, such as FRα, on the surface of 
tumor cells. They can mediate specific anti-tumor 
activity either by blocking cell signaling or by eliciting 
immune-mediated cell killing by engaging effector cells 
or complement. Examples of clinical trials of monoclonal 
antibodies directed against FRα are summarized in Table 
3 [70].
Farletuzumab
A mAb that has been widely studied in ovarian 
and lung cancers is farletuzumab, (MORab003). It is 
a fully humanized IgG1 antibody specific for FRα. 
Farletuzumab does not prevent binding of folate to its 
receptors, nor does it inhibit the transport of folate into 
the cell via the receptor. Instead, in vitro studies have 
demonstrated that farletuzumab exhibits activity against 
FRα-expressing tumor cells by a number of mechanisms. 
These include tumor cell killing by antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC), sustained tumor cell autophagy, and 
inhibition of Lyn kinase substrate phosphorylation [100-
104].
Farletuzumab was first given as monotherapy 
in a phase I trial in 25 patients with platinum-resistant 
ovarian cancer (NCT00428766). No dose-limiting 
toxicities (DLTs) were observed, and dose escalation was 
continued to a maximum 400 mg/m2 dose [105]. Safety 
of farletuzumab, in combination with carboplatin and 
liposomal doxorubicin, was then demonstrated in a phase 
Ib study in patients with platinum-sensitive ovarian cancer 
(NCT01004380) [106]. In a subsequent phase II study, 
patients with the same disease were given farletuzumab 
combined with carboplatin and a taxane, followed by 
farletuzumab maintenance therapy (NCT00318370). 
Response rates comparing favorably with historical 
controls were observed. Overall in these trials, 
farletuzumab was well tolerated as a single-agent, and did 
not seem to confer additive toxicity when combined with 
chemotherapy [107].
Following these promising results, a large phase 
III trial in patients with platinum-sensitive recurrent 
ovarian cancer was carried out (NCT00849667). In this 
trial, farletuzumab, in combination with carboplatin and 
a taxane, was compared to carboplatin/taxane treatment 
alone. The primary endpoint of improved PFS was not 
met, however subsequent analysis suggested an improved 
PFS in some patient subgroups given higher doses, and 
in those with lower CA125 levels [28]. Farletuzumab 
in combination with paclitaxel was also compared to 
paclitaxel alone in patients with platinum-resistant ovarian 
cancer in a second phase III study (NCT00738699), but 
this trial was discontinued early for futility.
Given that patients with high FRα-expressing tumors 
may derive greater benefit from farletuzumab therapy than 
those with low expression in tumors, future trials may 
involve the stratification of patients based on their tumor 
FRα expression. In fact, the manufacturer of farletuzumab 
has announced the development of a diagnostic assay to 
better identify patients with high FRα expression [108]. 
Furthermore, a phase II study comparing farletuzumab, 
in combination with carboplatin and paclitaxel, or with 
carboplatin and liposomal doxorubcin, is currently 
recruiting patients with platinum-sensitive ovarian cancer 
and low CA125 (NCT02289950). Another phase II trial 
will be conducted in patients with FRα-positive TNBC 
who have low serum levels of CA125 [109].
The clinical efficacy of farletuzumab, in 
combination with platinum-containing chemotherapy has 
also been evaluated in non-small-cell lung cancer. This 
phase II study (NCT01218516) enrolled 130 patients 
with stage IV adenocarcinoma of the lung and has now 
completed, although results are yet to be published. 
MOv18 IgG1
The MOv18 IgG1 murine monoclonal antibody 
was generated by immunization of mice with a surgical 
specimen of human ovarian carcinoma [32]. The FRα-
specific variable regions of the resultant antibody were 
cloned, and the murine γ1-heavy chains and κ-light chains 
were subsequently replaced with their human equivalents 
to engineer a chimeric version of MOv18 IgG [110]. 
Previous clinical studies of MOv18 IgG (either murine 
or chimeric) administered to ovarian cancer patients have 
suggested therapeutic benefit with no overt toxicity.
The first clinical administration of MOv18 IgG1 
was as a radiolabeled murine antibody (131I-MOv18 IgG1) 
in 1991. The main aim of this study was to investigate 
the feasibility of radioimmunoscintigraphy (RIS, the 
administration of a radiolabelled antibody against a 
tumor surface marker, for the purpose of imaging the 
tumor and any metastases). Another objective was to 
evaluate biodistribution of MOv18 IgG1 for further 
therapeutic applications [60]. A total of 30 patients with 
ovarian carcinoma were given 131I-MOv18 IgG1 either 
intravenously (i.v.) (n = 20) or intraperitoneally (i.p.) (n 
= 10). High tumor uptake, a good tumor to background 
ratio and low non-specific uptake in non-affected organs 
were observed, with i.p. administration superior to i.v. 
administration. These findings suggested that MOv18 
IgG1 represented a promising mAb for RIS in ovarian 
cancer.
Subsequently the same 131I-radiolabelled murine 
antibody was administered as i.p. radioimmunotherapy to 
16 ovarian cancer patients with minimal residual disease 
[111]. Efficacy was observed, with 5 complete responses 
and 5 patients demonstrating stable disease. In addition 
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the toxicity was reported to be low with only one patient 
showing mild and transient bone marrow suppression. 
However, human anti-mouse antibody (HAMA) 
production was demonstrated in 94% of patients.
In order to reduce HAMA, a chimeric MOv18 
IgG1 was generated, and radiolabeled with either 131I or 
125I, before administration to 24 patients with ovarian 
carcinoma [33]. Six days after injection, the antibody was 
demonstrated to localize well in ovarian carcinoma tissue 
with a mean tumor to normal tissue ratio of 6.7, indicating 
a prolonged accumulation in the tumor relative to normal 
tissues. In view of these positive findings, the safety of 
a single i.v. infusion of increasing doses (5-75mg) of 
chimeric MOv18 IgG1 was subsequently evaluated in 
a phase I study of 15 ovarian carcinoma patients [112]. 
Administration of MOv18 IgG1 was demonstrated to 
be safe with no significant changes in hematological, 
biochemical, or urine profiles detected. However, at doses 
of 50 mg and above all patients experienced minor (World 
Health Organization, WHO grade 2) side effects, including 
fever, headache, and nausea/vomiting. Interestingly, no 
human anti-chimeric antibody (HACA) response was 
detected up to 12 weeks post injection. These findings 
suggested that targeting of FRα with chimeric MOv18 
IgG1 was safe and that this mAb represented a promising 
therapeutic for the treatment of ovarian carcinoma.
Since ovarian cancer is mainly limited to the 
peritoneal cavity, locoregional delivery of therapeutics 
can be an option. Therefore the influence of the route 
of administration (i.v. or i.p.) of radiolabeled chimeric 
MOv18 IgG1 was investigated in two studies [61, 113]. In 
the first study, 131I-MOv18 IgG1 was administered to 12 
patients with ovarian cancer. Scintigraphic images after 
i.p. administration showed better accumulation in ovarian 
cancer lesions compared with after i.v. administration. 
Furthermore, there was no normal organ toxicity. This 
study concluded that the i.p. route of administration was 
safe and seemed to be preferable to i.v. administration 
[113]. In the second study 15 patients received chimeric 
MOv18IgG1 labeled with 131I, 125I and 123I, either via the 
i.p. or i.v. route. No adverse events and no HACA response 
were reported. Furthermore, in contrast to the previous 
study, no advantage could be demonstrated for the i.p. 
route of administration with respect to tumor uptake; 
however, it was suggested that it may be the preferred 
route with respect to bone marrow toxicity since the area 
under the curve (AUC) was significantly lower for the i.p. 
versus the i.v .route [61]. 
In summary, numerous clinical studies conducted 
with murine or chimeric MOv18 IgG1 to date suggest 
that targeting the tumor antigen FRα with a therapeutic 
mAb is safe, with minimal toxicities observed across all 
studies. However, some studies have suggested superior 
tumor targeting when the antibody was administered 
locoregionally to the tumor, perhaps indicating relatively 
poor tumor penetrance of MOv18 IgG1 when administered 
via the i.v. route. This suggests the possible benefit of 
undertaking antibody engineering strategies, including 
re-engineering approaches or changing the isotype of the 
antibody, with the aim of improving bioactivity, potency 
or tumor penetrance aimed at enhancing antibody efficacy. 
MOv19 and derivatives
The mAb MOv19 was selected from the same 
fusion from which MOv18 was derived. MOv19 and 
LK26 (the murine mAb from which the fully humanized 
Farletuzumab was derived) recognize the same or 
overlapping epitopes on FRα, but independent from the 
epitope recognized by MOv18, as detected by competition 
assay in Biacore analysis and ELISA [32, 114].
Chimeric versions of MOv18 and MOv19 IgG 
antibodies, similarly to Farletuzumab, mediate both ADCC 
[115] and low levels of CDC [116] in vitro. However, 
when the two chimeric mAbs were mixed, a significant 
increase in tumor cell killing was observed of up to 50%. 
This value increased to 70% after neutralization of CD46 
and CD59 (membrane C regulatory molecules) without 
an appreciable change of ADCC. These results suggest 
that complement can contribute to the killing of ovarian 
carcinoma cells induced by the mixture of cMOv18 and 
cMOv19.
Several different derivatives of MOv19 have been 
evaluated in different therapeutic applications. Completely 
human Fab fragments against FRα were produced by using 
phage display and among them one, named C4, exhibited 
good specificity [117]. The human C4 in scFv format, after 
adequate optimization, resulted in CAR redirection [118].
By applying epitope imprinting selection [119], 
a method that enables isolation of antibodies with the 
same specificity of a pre-existing antibody, a human Fab 
(AFRA5), recognizing a FRα epitope overlapping with 
that of MOv19, was identified [120]. After optimization 
of the lead reagent, a chemical dimer, named AFRA-
DFM5.3, was considered suitable for further in vivo 
preclinical evaluation in the perspective of a clinical 
use. In fact, an antibody fragment, in a dimer format 
that stabilizes binding as soon as the antigen-antibody 
complex is formed on the target tumor, might be the 
reagent of choice for i.p. radioimmunotherapy of ovarian 
cancer because of its relatively small size, which should 
favor tumor penetration and fast clearance. Due to its fast 
and high tumor uptake, 131I-AFRA-DFM5.3 resulted in 
more than 50% of treated animals cured in a preclinical 
intraperitoneal model [121]. The human origin of AFRA-
DFM5.3 and its efficacy when delivered locoregionally as 
an 131I reagent, together with evidence of the feasibility 
and acceptable toxicity profile of ovarian cancer treatment 
with anti-FR mAbs, could provide the basis for rational 
design of new therapeutic modalities.
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MOv18 IgE
MOv18 IgE is an anti-FRα chimeric IgE antibody, 
engineered from the variable heavy and light chain 
regions of MOv18 IgG1 in order to investigate the 
hypothesis that IgE antibodies may offer advantages as 
immunotherapeutic agents against cancer compared to 
their IgG counterparts [122]. The rationale for using IgE 
antibodies against cancer stems from the unique properties 
of this class, which make it a critical contributor to allergic 
and parasitic immune responses. These properties include 
the exceptionally high affinity of IgE to its Fc receptors 
(FcεRI and CD23), the lack of an inhibitory IgE receptor, 
and the significantly longer half-life of IgE in tissues 
compared to IgG1, which results in improved local 
retention of IgE. IgE antibodies are thus able to confer 
potent immune responses by activating tumor-resident 
immune effector cells [123].
To date, a number of in vivo models have been 
used to evaluate the efficacy of MOv18 IgE. Firstly, 
immunodeficient (SCID) mice challenged subcutaneously 
(s.c.) with FRα-expressing human ovarian carcinoma cells, 
were treated with human peripheral blood lymphocytes 
(PBLs) and MOv18 IgE or IgG1 antibodies i.v. [122]. 
Secondly, a xenograft mouse model was set-up using 
patient-derived FRα-expressing human ovarian carcinoma, 
and mice were given human peripheral blood mononuclear 
cells (PBMCs) i.p. with MOv18 IgE or IgG1 antibodies 
[124-126]. MOv18 IgE afforded superior anti-tumor 
efficacy and animal survival, compared with its IgG1 
counterpart, in both models. 
These studies also provided evidence that MOv18 
IgE efficacy may be mediated via anti-tumor effector cell 
functions in vivo: addition of PBMCs was required for the 
observed protective effect and this efficacy was ablated 
upon depletion of monocytes; monocytic infiltration was 
observed in tumor sections from mice treated with MOv18 
IgE; and large areas of tumor necrosis were detected 
following MOv18 IgE treatment [122, 126]. MOv18 IgE-
mediated tumor cell killing by human monocytes and 
eosinophils was also confirmed in vitro by ADCC/ADCP 
[126, 127]. Emerging evidence point to the capacity of IgE 
antibodies to activate host immune effector cells against 
cancer and support its anti-tumor efficacy [128-131]. This 
agent is now being translated for clinical testing in FRα-
expressing carcinomas.
T cell activating strategies
The possibility to combine the antibody specificity 
with the potency of T cell weapons to treat tumors, 
independently from the T cell receptor (TcR)-defined 
specificity, and expression of human leukocyte antigen 
(HLA) on cancer cells, has been explored and specific 
reagents for T cell retargeting were developed. Among 
different approaches, the most promising are the use 
of bi-specific antibodies (BsAbs), T-cell engineering 
to create chimeric antigen receptors (CARs), as well as 
combinations with immune checkpoint inhibitors.
Adoptive transfers of ex vivo T cells armed with 
the BsAb OC/TR (MOv18 x anti-CD3) [132] or of CAR-
engineered T cells recognizing FRα [133] (Table 2) were 
among the first clinical attempts with these therapeutic 
tools. 
In a phase I/II study, among the 28 ovarian cancer 
patients treated intraperitoneally with OC/TR-armed 
activated T cells and IL-2, response to treatment could 
be assessed in 26 patients by explorative laparotomy. 
The overall intraperitoneal response rate was 27%. The 
complete responses seen in three patients lasted 26 months 
in one patient, 23 months in the second, and 18 months in 
the third [132]. On the contrary the outcome of the phase 
I clinical trial with a FRα-specific CAR T cell treatment 
was discouraging with no response observed in any 
patient and the presence of significant toxicities [133]. It 
is noteworthy that both trials have been conducted using 
the anti-FRα murine monoclonal antibody MOv18 (see 
further discussion of this antibody below) and that in the 
OC/TR trial almost all the patients developed a HAMA 
response that precluded further treatment [134] and in the 
CAR trial an inhibitory factor developed in the serum of 
three of six patients tested over the period of treatment, 
which significantly reduced the ability of gene-modified 
T cells to respond against FRα positive tumor cells [133].
Even if no clinical results are at present available 
with these anti-FRα tools, advances in protein engineering 
and increased knowledge in T cell biology have enabled 
the rise of both BsAbs and CARs from inefficient first 
generation reagents to promising molecules for cancer 
treatment. In particular, first generation CARs failed 
because of poor T cell expansion and adverse effects; new 
second and third generation CARs have solved at least in 
part these problems and good pre-clinical in vivo results, 
i.e. tumor regression, longer persistence in circulation and 
better localization towards the tumor, have been obtained 
with MOv19-based CAR constructs containing the co-
stimulatory motif of CD137 or CD27 [118, 135].
Another approach, which has recently seen 
increased interest, is the use of antibodies targeting 
immune cell checkpoints that negatively regulate anti-
tumor immunity [136]. Ipilimumab targets cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4), which is 
involved in an alternative interaction between T cells and 
antigen-presenting cells (APCs) that inhibits T cell effector 
functions. Similarly, nivolumab and pembrolizumab target 
the interaction between programmed cell death receptor 
1 (PD-1), which is expressed on activated effector cells 
such as T cell, B cells and other myeloid cells, and its 
ligand PD-L1, which is expressed on tumor cells and 
APCs. Treatment with these immune checkpoint-targeting 
antibodies prevents the attenuation of T cell activation and 
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thereby enhances anti-tumor immunity. Ipilimumab and 
nivolumab have shown significant efficacy in patients 
with metastatic melanoma and are now widely approved 
for treatment of this solid tumor. Clinical trials in patients 
with other tumor types, including ovarian, lung and breast, 
are now underway and demonstrating promising results 
[137-140]. Thus, the combination of checkpoint inhibitors 
and FRα-targeting strategies may well lead to greater 
therapeutic success.
CONCLUSIONS
Insights into tumor expression and distribution of 
FRα and its emerging roles in cancer growth and metastasis 
are now focusing renewed interest on this tumor-
associated antigen as a potential target and tumor marker 
for solid tumours such as ovarian, lung and basal breast 
cancers. There is an unmet need in these malignancies, 
associated with particularly poor prognosis, for further 
treatment options as well as biomarkers (predictive and 
prognostic). Future focus on FRα offers real potential for 
the development of targeted cancer therapies. Past and 
ongoing clinical evaluations of FRα-targeted therapies, 
such as vintafolide and farletuzumab, allow for cautious 
optimism, but suggest that both improved patient selection 
and optimised modes of action are still needed. 
Low levels of FRα expression in most normal 
tissues predict a low probability of significant toxicity for 
these agents, supported by clinical experience so far with 
treatment strategies targeted using folate and antibodies. 
FRα expression in tumor may serve as both a predictive 
marker to guide patient selection for such strategies, and 
also as a potential prognostic indicator. Furthermore, 
serum detection of circulating soluble antigen levels might 
also serve as an effective diagnostic or prognostic marker, 
and potentially an indicator of treatment response. These 
possible uses still require further study in FRα-expressing 
malignant indications. 
A range of novel immunotherapeutic modalities, 
including vaccines, oncolytic viruses, monoclonal 
antibodies and adoptive T-cell strategies, with novel 
mechanisms of action, are in preclinical or clinical studies. 
Perhaps those agents with enhanced immune activating 
properties, more resistant to tumor-associated immune 
suppressive mechanisms, may in future become effective 
strategies against FRα-expressing tumors.
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